US yes for Biogen Idec hemophilia drug Alprolix
This article was originally published in Scrip
Executive Summary
Biogen Idec's Alprolix has become the first long-acting recombinantFactor IX product to gain US FDA approval for the prevention or reduction of the frequency of bleeding episodes in hemophilia B. The firm plans to start rolling it out commercially in early May.